I recently came across yet another article suggesting that cross-reactive memory T cells serve a critical role in protecting COVID-19 contacts against infection and thereby abrogate subsequent induction of de novo SARS-CoV-2-specific antibody responses: https://www.nature.com/articles/s41467-021-27674-x.pdf.
I do not concur with the suggestion of the authors that pre-existing cross-reactive memory T cells could be responsible for protection against infection (i.e., by causing abrogation of infection). The association / correlation between pre-existing IL-2-secreting cross-reactive T cells and protection from infection in COVID-19 contacts does not imply causality. Whereas there can be no doubt that pre-existing cross-reactive CoV-specific T cells are boosted in COVID-19 contacts, there is no proof that these cells are responsible for controlling infection and abrogating subsequent induction of de novo SARS-CoV-2-specific antibody responses in COVID-19 contacts.
Exposure-mediated boosting of pre-existing cross-reactive memory T cells requires antigen (Ag) presentation as neither ORF-1 nor N(1) are presented on the surface of infected cells at an early stage of SARS-CoV-2 infection. In order for these early proteins to be presented by Ag-presenting cells, virus-infected target host cells must be lysed at an early stage of infection (see my comments to a similar paper: here). There is no evidence, however, that pre-existing cross-reactive memory T cells have such cytolytic capacity. This is in sharp contrast to Natural Killer (NK) cells, which have been postulated to synergize with innate IgM-secreting B1 cells to enable elimination of virus-infected cells at an early stage of viral infection (R. Carsetti et al., https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7772470/pdf/fimmu-11-610300.pdf).
In other words, boosting of pre-existing cross-reactive memory T cells is to be considered the consequence but not the cause of abrogation of infection at an early stage of infection. The role of innate immune effector lymphocytes (IgM-secreting B1 cells and NK cells) in controlling SARS-CoV2 infection still seems contradictive as it is not within the conventional paradigm of immunology, let alone vaccinology. This is highly problematic as the possible misinterpretation of immune mechanisms underlying the expansion of pre-existing cross-reactive memory T cells leads some scientists to support the inclusion of non-spike antigens (i.e., including cross-reactive T cell epitopes) in second-generation vaccines. This will only bring grist to the mill of those addicted to the mass vaccination program and claiming that such novel vaccines will protect against novel SARS-CoV-2 variants with potential to escape naturally acquired or vaccine-induced humoral immunity.
Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.
Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.
Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.